MX387180B - Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn). - Google Patents
Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn).Info
- Publication number
- MX387180B MX387180B MX2016008540A MX2016008540A MX387180B MX 387180 B MX387180 B MX 387180B MX 2016008540 A MX2016008540 A MX 2016008540A MX 2016008540 A MX2016008540 A MX 2016008540A MX 387180 B MX387180 B MX 387180B
- Authority
- MX
- Mexico
- Prior art keywords
- fcrn
- neonatal
- receptor
- binding properties
- region variants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un polipéptido que comprende un primer polipéptido y un segundo polipéptido que comprende cada uno en dirección de N-terminal a C-terminal al menos una porción de una región bisagra de inmunoglobulina, que comprende uno o más residuos de cisteína, un dominio CH2 de inmunoglobulina y un dominio CH3 de inmunoglobulina, en donde i) el primer y segundo polipéptido comprenden las mutaciones H310A, H433A y Y436A, o ii) el primer y segundo polipéptido comprende las mutaciones L251D, L314D y L432D, o iii) el primer y segundo polipéptido comprende las mutaciones L251S, L314S y L432S.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14151319 | 2014-01-15 | ||
| EP14165922 | 2014-04-25 | ||
| PCT/EP2015/050425 WO2015107025A1 (en) | 2014-01-15 | 2015-01-12 | Fc-region variants with modified fcrn-binding properties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016008540A MX2016008540A (es) | 2016-09-26 |
| MX387180B true MX387180B (es) | 2025-03-18 |
Family
ID=52462893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008540A MX387180B (es) | 2014-01-15 | 2015-01-12 | Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn). |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170037121A1 (es) |
| EP (1) | EP3094649A1 (es) |
| JP (2) | JP6873701B2 (es) |
| KR (1) | KR20160104009A (es) |
| CN (2) | CN105873948B (es) |
| AR (1) | AR099079A1 (es) |
| BR (1) | BR112016016411A2 (es) |
| CA (1) | CA2931979A1 (es) |
| MX (1) | MX387180B (es) |
| RU (1) | RU2730592C2 (es) |
| WO (1) | WO2015107025A1 (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| JP5764677B2 (ja) | 2011-02-28 | 2015-08-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合タンパク質 |
| CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
| EP2970508A4 (en) * | 2013-03-15 | 2016-12-14 | Permeon Biologics Inc | GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE |
| BR112016006929A2 (pt) * | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
| CN112877291A (zh) | 2014-04-10 | 2021-06-01 | 西雅图儿童医院 (Dba西雅图儿童研究所) | 基因修饰的t细胞产品、其制备方法和用途 |
| SG10201913507SA (en) | 2014-05-02 | 2020-02-27 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| WO2017027325A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| MX2018005036A (es) * | 2015-10-29 | 2018-08-01 | Hoffmann La Roche | Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes. |
| ES2972740T3 (es) | 2016-03-02 | 2024-06-14 | Momenta Pharmaceuticals Inc | Procedimientos relacionados con construcciones de Fc modificadas genéticamente |
| CA3016563A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| PL3484514T3 (pl) | 2016-05-23 | 2024-04-29 | Momenta Pharmaceuticals, Inc. | Kompozycje i sposoby związane z projektowanymi konstruktami Fc |
| JP7308034B2 (ja) | 2016-07-01 | 2023-07-13 | リゾルブ セラピューティクス， エルエルシー | 最適化二重ヌクレアーゼ融合物および方法 |
| EP3526246A1 (en) * | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| BR112019013955A2 (pt) | 2017-01-06 | 2020-02-11 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos de fc manipulados |
| US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
| US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| WO2019040674A1 (en) * | 2017-08-22 | 2019-02-28 | Sanabio, Llc | SOLUBLE INTERFERON RECEPTORS AND USES THEREOF |
| EP3728327A1 (en) * | 2017-12-22 | 2020-10-28 | F. Hoffmann-La Roche AG | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| US20190218285A1 (en) * | 2018-01-18 | 2019-07-18 | Molecular Cloning Laboratories (MCLAB) LLC | Long-Acting Therapeutic Fusion Proteins |
| WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP3870331B1 (en) * | 2018-10-25 | 2025-07-23 | F. Hoffmann-La Roche AG | Modification of antibody fcrn binding |
| KR102605376B1 (ko) | 2018-12-31 | 2023-11-23 | 삼성디스플레이 주식회사 | 표시 장치 |
| CN114127112A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
| EP3927744A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| EP3927746A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| EP4084823A4 (en) | 2020-01-03 | 2024-05-15 | Marengo Therapeutics, Inc. | ANTI-TCR ANTIBODY MOLECULES AND THEIR USES |
| CA3180321A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| AU2021288464A1 (en) * | 2020-06-08 | 2023-01-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-CD171 chimeric antigen receptors |
| WO2022046920A2 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| JP2023540248A (ja) | 2020-08-26 | 2023-09-22 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法 |
| GB2616128A (en) | 2020-08-26 | 2023-08-30 | Marengo Therapeutics Inc | Antibody molecules that bind to NKp30 and uses thereof |
| EP4295154A1 (en) * | 2021-02-18 | 2023-12-27 | F. Hoffmann-La Roche AG | Method for resolving complex, multistep antibody interactions |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| WO2022265331A1 (ko) * | 2021-06-14 | 2022-12-22 | 고려대학교 산학협력단 | 제어된 면역 작용 기작과 증가된 혈중 반감기를 갖는 fc변이체들 |
| KR20250096834A (ko) * | 2022-11-02 | 2025-06-27 | 베이징 창핑 래보러토리 | 융합 단백질 및 이의 용도 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2026011013A1 (en) | 2024-07-02 | 2026-01-08 | Epibiologics, Inc. | Binding agents and uses thereof |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP4685764B2 (ja) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変 |
| WO2005077981A2 (en) * | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| US7923538B2 (en) * | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| EP2407548A1 (en) * | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
| CA2759333A1 (en) * | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
| JP2014501725A (ja) * | 2010-11-24 | 2014-01-23 | グラクソ グループ リミテッド | Ｈｇｆを標的とする多特異的抗原結合タンパク質 |
| CN103443126B (zh) * | 2011-01-06 | 2016-11-23 | 葛兰素集团有限公司 | 结合TGFβ受体II的配体 |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| CA2850824C (en) * | 2011-10-13 | 2023-01-03 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
| AU2012332021B8 (en) * | 2011-11-04 | 2017-10-12 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| WO2013166594A1 (en) * | 2012-05-10 | 2013-11-14 | Zymeworks Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain |
| AU2013285355A1 (en) * | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| SG10201810481UA (en) * | 2013-04-29 | 2018-12-28 | Hoffmann La Roche | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
| EP3628685A1 (en) * | 2013-04-29 | 2020-04-01 | F. Hoffmann-La Roche AG | Human fcrn-binding modified antibodies and methods of use |
-
2015
- 2015-01-12 CA CA2931979A patent/CA2931979A1/en active Pending
- 2015-01-12 MX MX2016008540A patent/MX387180B/es unknown
- 2015-01-12 WO PCT/EP2015/050425 patent/WO2015107025A1/en not_active Ceased
- 2015-01-12 KR KR1020167019016A patent/KR20160104009A/ko not_active Ceased
- 2015-01-12 CN CN201580003633.0A patent/CN105873948B/zh active Active
- 2015-01-12 EP EP15703229.3A patent/EP3094649A1/en active Pending
- 2015-01-12 BR BR112016016411A patent/BR112016016411A2/pt not_active IP Right Cessation
- 2015-01-12 RU RU2016133345A patent/RU2730592C2/ru active
- 2015-01-12 CN CN202110445639.0A patent/CN113248613B/zh active Active
- 2015-01-12 JP JP2016546942A patent/JP6873701B2/ja active Active
- 2015-01-13 AR ARP150100075A patent/AR099079A1/es unknown
-
2016
- 2016-07-14 US US15/210,218 patent/US20170037121A1/en not_active Abandoned
-
2018
- 2018-04-06 US US15/947,377 patent/US20190016792A1/en not_active Abandoned
-
2021
- 2021-04-21 JP JP2021071749A patent/JP7686437B2/ja active Active
-
2023
- 2023-07-11 US US18/220,623 patent/US20240218060A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170037121A1 (en) | 2017-02-09 |
| CN105873948A (zh) | 2016-08-17 |
| KR20160104009A (ko) | 2016-09-02 |
| BR112016016411A2 (pt) | 2017-10-03 |
| JP7686437B2 (ja) | 2025-06-02 |
| CN113248613A (zh) | 2021-08-13 |
| JP2021113214A (ja) | 2021-08-05 |
| JP2017505768A (ja) | 2017-02-23 |
| US20240218060A1 (en) | 2024-07-04 |
| HK1223951A1 (zh) | 2017-08-11 |
| JP6873701B2 (ja) | 2021-05-19 |
| CA2931979A1 (en) | 2015-07-23 |
| WO2015107025A1 (en) | 2015-07-23 |
| CN105873948B (zh) | 2021-04-13 |
| EP3094649A1 (en) | 2016-11-23 |
| RU2016133345A3 (es) | 2018-10-31 |
| RU2730592C2 (ru) | 2020-08-24 |
| MX2016008540A (es) | 2016-09-26 |
| RU2016133345A (ru) | 2018-02-20 |
| AR099079A1 (es) | 2016-06-29 |
| CN113248613B (zh) | 2024-08-23 |
| US20190016792A1 (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX387180B (es) | Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn). | |
| MX382848B (es) | Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas. | |
| MX380658B (es) | Variantes de region fc con union mejorada de la proteina a. | |
| CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
| PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| MX378451B (es) | Variantes de regiòn fc con uniòn del receptor fc neonatal (fcrn) modificado y mètodos de uso. | |
| MX2023008559A (es) | Proteínas de fusión fc heterodiméricas il15/il15ra. | |
| EA201690469A1 (ru) | Слитый белок | |
| MX2017006866A (es) | Pares de unión para producción de péptidos. | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| EA201591700A1 (ru) | Гибридные белки апелина и их применение | |
| SG10201909716RA (en) | Modified j-chain | |
| EP4438621A3 (en) | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use | |
| MX2020003260A (es) | Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso. | |
| EA032960B1 (ru) | Антитела, содержащие химерные константные домены | |
| MX2015012553A (es) | Variantes de fc. | |
| EP3888690A3 (en) | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties | |
| WO2017006052A3 (fr) | UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE | |
| MX387560B (es) | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. | |
| EP3705494A3 (en) | Antibodies against frizzled proteins and methods of use thereof | |
| MX2020002934A (es) | Variantes de anticuerpos. | |
| AR099080A1 (es) | Variantes de región fc con propiedades de unión a fcrn (receptor fc neonatal) modificadas y de unión a proteína a mantenidas | |
| EA202090582A2 (ru) | ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ | |
| EA201991576A1 (ru) | Частичные агонисты инсулинового рецептора | |
| TH1501005499A (th) | โพลีเปปไทด์ IL-22 และฟิวชันโปรตีน IL-22 Fc และวิธีการใช้ |